Following the December 15 FDA approval of the trastuzumab deruxtecan (T-DXd) plus pertuzumab regimen, clinicians are transitioning to a new first-line standard for metastatic HER2-positive breast cancer. This shift requires rigorous toxicity monitoring, particularly for interstitial lung disease (ILD) and cardiac function, alongside individualized management of symptomatic patients.
New Frontline Standards: The Shift to T-DXd Plus Pertuzumab
The treatment landscape for metastatic HER2-positive breast cancer has undergone a significant transformation. As reported by Oncologynewscentral, the U.S. Food and Drug Administration approved the combination of trastuzumab deruxtecan (T-DXd) and pertuzumab on December 15. This decision, driven by results from the DESTINY-Breast09 trial, effectively replaces the long-standing taxane-based CLEOPATRA regimen as the preferred first-line option.
Aditya Bardia, MD, MPH, director of translational research integration at the Jonsson Comprehensive Cancer Center at the University of California Los Angeles, emphasized the clinical impact of this change. For patients with metastatic HER2-positive breast cancer, this is now the preferred first-line treatment option,
Dr. Bardia noted, citing improvements in progression-free survival and higher rates of complete response compared to the older standard of care.
While the combination is now standard, questions persist regarding optimal duration. Dr. Bardia pointed out that while the CLEOPATRA regimen involved a transition to maintenance therapy after six to eight cycles of chemotherapy, the current T-DXd labeling and the underlying clinical trial data suggest continuing treatment until disease progression or unacceptable toxicity. Ongoing research, such as the DEMETHER study, aims to provide further clarity on potential maintenance strategies.
Managing Treatment-Emergent Toxicities and Patient Safety
The move to T-DXd-based therapy necessitates a heightened focus on safety, specifically regarding pulmonary and cardiac health. According to Cancernetwork, clinicians must maintain a low threshold for investigating respiratory symptoms, such as a mild cough, which can serve as early warning signs for interstitial lung disease (ILD).
The management protocol for patients on T-DXd often involves multidisciplinary coordination. When respiratory symptoms arise, providers are advised to utilize oxygen saturation assessments and high-resolution chest CT scans. Distinguishing ILD from other common issues, such as seasonal respiratory viruses, is critical to avoid unnecessary treatment interruptions while ensuring patient safety.
Beyond ILD, Dr. Bardia noted other side effects:
- Gastrointestinal distress: Nausea is the most common side effect, typically managed with a three-drug antiemetic regimen, including olanzapine for breakthrough symptoms.
- Cardiac monitoring: As with all anti-HER2 therapies, there is a risk of decreased ejection fraction, requiring regular echocardiograms throughout the course of treatment.
Individualized Care and Long-Term Sustainability
Effective oncology care is increasingly defined by the ability to balance aggressive systemic therapy with a patient’s quality of life. In a roundtable discussion hosted by Ascopost, experts discussed managing targeted therapy for hormone receptor–positive/HER2-negative breast cancer. Dr. Erika Hamilton, Chief Development Officer, Late Phase, and Director of the Breast Cancer Research Program at Sarah Cannon Research Institute, participated in the discussion regarding adverse event management and longitudinal care strategies to keep patients on effective therapy.
This individualized approach is supported by cases of exceptional response. A report published by Frontiers in Oncology detailed a patient who remained on T-DM1 therapy for more than six years—totaling 107 cycles—after achieving stability in both systemic disease and brain metastases. This case underscores that, with rigorous surveillance and proactive symptom management, long-term therapeutic benefit is possible even in complex, metastatic scenarios.
For clinicians, the primary challenge remains navigating scenarios where data may be incomplete. As treatment options evolve, the integration of palliative care, internal medicine reviews for polypharmacy, and multidisciplinary team assessments remains essential for maintaining long-term treatment sustainability.
Consult your healthcare provider for personalized medical advice and to discuss how these treatment guidelines may apply to your specific diagnosis.
Worth a look
